Budesonide/formoterol maintenance and reliever therapy at two different maintenance doses Source: Annual Congress 2009 - New bronchodilators Year: 2009
Budesonide/formoterol maintenance and reliever therapy compared with conventional best standard treatment Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Budesonide/formoterol maintenance and reliever therapy compared to conventional best practice in the treatment of persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 616s Year: 2007
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
Budesonide/formoterol for maintenance and reliever therapy in real-life in Thailand Source: Annual Congress 2010 - Treatment options for asthma Year: 2010
Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: Eur Respir J, 51 (1) 1701688; 10.1183/13993003.01688-2017 Year: 2018
Patient characteristics to determine an appropriate maintenance dose of budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009
Formoterol as relief medication is increasingly more effective than salbutamol in patients with increasing need for reliever therapy Source: Eur Respir J 2003; 22: Suppl. 45, 235s Year: 2003
Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective? Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008
Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007
Stability of overall asthma control achieved with budesonide/formoterol maintenance + reliever therapy Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy Source: Eur Respir J 2010; 36: 524-530 Year: 2010
Budesonide/formoterol for maintenance and relief vs. higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS) Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment Year: 2007
Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005
The inhaled corticosteroid/long-acting ß-agonist maintenance and reliever therapy regimen: where to from here? Source: Eur Respir J, 51 (1) 1702338; 10.1183/13993003.02338-2017 Year: 2018
Budesonide/formoterol is a well-tolerated long term maintenance therapy for COPD Source: Eur Respir J 2005; 26: Suppl. 49, 287s Year: 2005
Budesonide/formoterol provides better efficacy at a lower or similar cost as compared to high-dose salmeterol/fluticasone treatment Source: Annual Congress 2007 - Cost-effectiveness in diagnosis, therapy and care Year: 2007
Budesonide/formoterol reduces the use of oral corticosteroids in the treatment of COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003